Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G L Kemp

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Angiology|October 1, 1971
The Q-T ratio in treadmill stress testingG L Kemp
Journal of the American Geriatrics Society|June 1, 1972
Treatment of ventricular ectopic rhythms with diphenylhydantoinG L Kemp
Heart & Lung : the Journal of Critical Care|March 1, 1973
Electrocardiogram abnormalities discovered with treadmill stress testingG L Kemp
The American Journal of Cardiology|November 1, 1972
Value of treadmill stress testing in variant angina pectorisG L Kemp
California Medicine|February 1, 1972
Coronary arteriographyG L Kemp
Diabetes, Obesity & Metabolism|September 20, 2014
Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetesA P Sykes, G L Kemp, R Dobbins, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Angiology|October 1, 1971
The Q-T ratio in treadmill stress testingG L Kemp
Journal of the American Geriatrics Society|June 1, 1972
Treatment of ventricular ectopic rhythms with diphenylhydantoinG L Kemp
Heart & Lung : the Journal of Critical Care|March 1, 1973
Electrocardiogram abnormalities discovered with treadmill stress testingG L Kemp
The American Journal of Cardiology|November 1, 1972
Value of treadmill stress testing in variant angina pectorisG L Kemp
California Medicine|February 1, 1972
Coronary arteriographyG L Kemp
Diabetes, Obesity & Metabolism|September 20, 2014
Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetesA P Sykes, G L Kemp, R Dobbins, et al.
Pageof 1